TOA EIYO LTD

Fukushima-shi, Japan

TOA EIYO LTD

Fukushima-shi, Japan

Time filter

Source Type

Patent
Toa Eiyo Ltd. | Date: 2015-02-13

Provided is a novel compound having an excellent suppression effect against arrhythmia including atrial fibrillation and being useful as a pharmaceutical product without antiviral effect. Disclosed is a compound represented by the following General Formula (I), a pharmaceutically acceptable salt thereof, or a solvate thereof (in the formula, the dotted line portion represents a single bond or a double bond; R^(1 )represents an optionally substituted C_(1-6 )alkyl group; Q represents an oxygen atom, a sulfur atom, or NR^(5); R^(2 )represents (CO)R^(6), CHR^(6)R^(7), or CH_(2)OR^(8); and R^(3 )and R^(4), which may be identical or different, each represent an amino group, an azide group, or XR^(9), with the proviso that any one of R^(3 )and R^(4 )is an amino group).


Patent
TOA Eiyo Ltd. | Date: 2017-04-05

Provided is a compound which is useful as a prophylactic or therapeutic agent for various diseases in which T-type calcium channels are involved, such as hypertension, arrhythmia, pain and cancers, the compound having antagonistic activity against T-type calcium channels, being highly stable in the body and having low risk of, for example, genotoxicity. Disclosed is a compound represented by the following general formula (I), a pharmaceutically acceptable salt thereof, or a solvate thereof:^(1) represents -NH(C=O)-V-R^(3) or - (C=O)NH-V-R^(3);V represents a single bond, methylene, or -C(CH_(3))_(2)O-;R^(2) represents a optionally substituted C_(1-6) alkyl group;X represents a hydrogen atom, an oxygen atom, a hydroxyl group, a methyl group, or a methylene group;A represents -NR^(6)-, -O-CH_(2)-, or -S-CH_(2)-;n represents the number of methylene chains and represents an integer of 0, 1 or 2; anda doublet containing a dotted line represents a single bond or a double bond.


Patent
TOA Eiyo Ltd. | Date: 2015-02-25

Provided is a pharmaceutical agent containing a compound represented by General Formula (1), a pharmaceutically acceptable salt thereof, or a solvate thereof:_(1)-C_(3) linear alkylene group, in which one methylene group is optionally substituted with O or S;n represents an integer of from 3 to 5;X^(1) and X^(2) each independently represent CH or N;W^(1) and W^(2) each independently represent a carboxyl group or a tetrazolyl group;V represents a C_(1)-C_(8) linear or branched alkylene group, in which one methylene group is optionally substituted with O or S; andR represents a substituted phenyl group, for example.


Patent
Toa Eiyo Ltd. | Date: 2014-10-14

Provided is a pharmaceutical agent containing a compound represented by general formula (1), a pharmaceutically acceptable salt thereof or a solvate thereof. A compound represented by general formula (1), a pharmaceutically acceptable salt thereof or a solvate thereof; wherein Ar represents an aryl group, or a 5- or 6-membered heteroaryl group containing a nitrogen atom, an oxygen atom or a sulfur atom; Y represents, for example, a hydrogen atom or a C_(1)-C_(6 )alkyl group; A represents a C_(1)-C_(3 )alkylene chain which may be substituted with two C_(1)-C_(2 )alkyl groups; X represents a hydrogen atom or a halogen atom; V represents an oxygen atom or a methylene chain; and R represents a group selected from the formulae below.


Patent
TOA Eiyo Ltd. | Date: 2016-12-21

Provided is a novel compound having an excellent suppression effect against arrhythmia including atrial fibrillation and being useful as a pharmaceutical product without antiviral effect. Disclosed is a compound represented by the following General Formula (I), a pharmaceutically acceptable salt thereof, or a solvate thereof (in the formula, the dotted line portion represents a single bond or a double bond; R^(1) represents an optionally substituted C_(1-6) alkyl group; Q represents an oxygen atom, a sulfur atom, or NR^(5); R^(2) represents - (C=O)-R^(6), -CHR^(6)R^(7), or-CH_(2)OR^(8); and R^(3) and R^(4), which may be identical or different, each represent an amino group, an azide group, or -X-R^(9), with the proviso that any one of R^(3) and R^(4) is an amino group).


Patent
TOA Eiyo Ltd. | Date: 2016-08-24

Provided is a pharmaceutical agent containing a compound represented by general formula (1), a pharmaceutically acceptable salt thereof or a solvate thereof. A compound represented by general formula (1) , a pharmaceutically acceptable salt thereof or a solvate thereof; wherein Ar represents an aryl group, or a 5- or 6-membered heteroaryl group containing a nitrogen atom, an oxygen atom or a sulfur atom; Y represents, for example, a hydrogen atom or a C_(1)-C_(6) alkyl group; A represents a C_(1)-C_(3) alkylene chain which may be substituted with two C_(1)-C_(2) alkyl groups; X represents a hydrogen atom or a halogen atom; V represents an oxygen atom or a methylene chain; and R represents a group selected from the formulae below.


Patent
Toa Eiyo Ltd. | Date: 2013-04-15

Provided is a pharmaceutical agent containing a compound represented by General Formula (1), a pharmaceutically acceptable salt thereof, or a solvate thereof: wherein A represents a C_(1)-C_(3 )linear alkylene group, in which one methylene group is optionally substituted with O or S;n represents an integer of from 3 to 5;X^(1 )and X^(2 )each independently represent CH or N;W^(1 )and W^(2 )each independently represent a carboxyl group or a tetrazolyl group;V represents a C_(1)-C_(8 )linear or branched alkylene group, in which one methylene group is optionally substituted with O or S; andR represents a substituted phenyl group, for example.


Patent
Nitto Denko Corporation and TOA Eiyo Ltd. | Date: 2014-05-21

A purpose of the present invention is to provide a packaging structure for a patch, in which the patch can be easily taken out of a package body. The packaging structure (100) for a patch includes a first and second base materials (120, 130) which have a peripheral edge part laminated with each other, and the patch is included therein. The first and second base materials (120, 130) have a first to forth sides (121 to 124, 131 to 134). At least one of the first and second base materials (120, 130) has a first to third opening parts (125 to 127, 135 to 137). The first to third opening parts (125 to 127, 135 to 137) guides so as to open toward the inner peripheral edge (120c1, 120c2, 120c4, 130c1, 130c2, 130c4) of the sealing part (120c, 130c).


Patent
Nitto Denko Corporation and TOA Eiyo Ltd. | Date: 2013-01-02

The invention is intended to provide an adhesive patch which effectively inhibits the occurrence of oozing out or sticking out of the adhesive layer components from the exposed area of the adhesive layer of the adhesive patch during storage as well as the occurrence of oozing of bisoprolol or a salt thereof from the adhesive layer thereby preventing the reduction in drug content. The support, the release liner and the adhesive layer constituting the adhesive patch each are formed to have a rectangular planar shape and the entire adhesive patch are formed to have a rectangular planar shape, and a protrudent part is formed on the support-side surface of the adhesive patch at a corner thereof. In addition, the adhesive patch may be formed to have a middle part and a peripheral part, and the protrudent part may be formed at a corner of the rectangular middle part. Further, between the adjacent at least two protrudent parts, a connecting built-up part may be provided in which the thickness of the adhesive patch is smaller than the thickness of the adhesive patch in the protrudent part. In case where the release liner has a split part, the split part is made so as not to traverse the protrudent part.


Patent
TOA Eiyo Ltd. | Date: 2013-04-10

Provided is a novel compound which shows an antagonistic effect against T-type calcium channels, and is useful as a pharmaceutical product. A compound represented by general formula (I), and a pharmaceutical agent containing the same, are disclosed:6-membered fused aromatic ring, and is 0, 1 or 2; p represents the number of nitrogen atoms contained in the 6-membered aromatic ring, and is 0 or 1; X represents an oxygen atom, -SO_(2)- or -N(R^(9))-; and R^(1) to R^(5) each represents a hydrogen atom or other substituents.

Loading TOA EIYO LTD collaborators
Loading TOA EIYO LTD collaborators